Who are Neurocrine Biosciences, Inc.'s main suppliers?

Neurocrine Biosciences, Inc. (NBIX) key suppliers include: Maze Therapeutics, Inc., Aardvark Therapeutics, Inc., Eton Pharmaceuticals, Inc., Lexeo Therapeutics, Inc., MapLight Therapeutics, Inc. and 10 more. View the full supplier network at chainsifter.com/chain/NBIX.

Who are Neurocrine Biosciences, Inc.'s major customers?

Neurocrine Biosciences, Inc. (NBIX) key customers include: CRENESSITY, SPECIALTY-PHARMACY-PROVIDERS, Eton Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Lexeo Therapeutics, Inc. and 24 more. View the full customer network at chainsifter.com/chain/NBIX.

What sector is Neurocrine Biosciences, Inc. in?

Neurocrine Biosciences, Inc. (NBIX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Neurocrine Biosciences, Inc. Suppliers, Customers & Supply Chain (NBIX)

15Suppliers

29Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Neurocrine Biosciences, Inc. (NBIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

47Total relationships

4Distinct source URLs

6High confidence

0.728Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Neurocrine Biosciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MAZE	Maze Therapeutics, Inc.	85%	Reciprocal relationship from MAZE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE g…
AARD	Aardvark Therapeutics, Inc.	72%	Reciprocal relationship from AARD graph: , operating results, prospects or financial condition. Risks Related to Artificial Intelligence We may use certain artificial intelligence (AI) technologies, …
ETON	Eton Pharmaceuticals, Inc.	72%	Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON g…
LXEO	Lexeo Therapeutics, Inc.	72%	Reciprocal relationship from LXEO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO g…
MPLT	MapLight Therapeutics, Inc.	72%	Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected …
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to r…
ORANY	ORANY	72%	prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o…
SLNO	Soleno Therapeutics, Inc.	72%	Reciprocal relationship from SLNO graph: ase obligations $ 1,849 $ - Purchases of property and equipment included in accounts payable $ 4 $ - See accompanying notes to condensed consolidated financia…
SPRB	Spruce Biosciences, Inc.	72%	Reciprocal relationship from SPRB graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SPRB graph: . The following table summarizes the Company's financial assets measured at …
TKPHF	Takeda Pharmaceutical Company Limited	72%	prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to r…
VTYX	Ventyx Biosciences Inc	72%	Reciprocal relationship from VTYX graph: ket disruptions, whether as a result of the military conflict between Russia and Ukraine and effects of the Russian sanctions, geopolitical tensions, volatile…
VYGR	Voyager Therapeutics, Inc.	72%	Reciprocal relationship from VYGR graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from VYGR g…
XENE	Xenon Pharmaceuticals Inc.	72%	Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to re…
XENE	Xenon Pharmaceuticals Inc.	72%	prepare to bring new therapies to market. Manufacturing and Supply We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA, CRENESSITY, and o…

Neurocrine Biosciences, Inc. Customers

Ticker	Name	Confidence	Evidence
CRENESSITY	CRENESSITY	92%	In addition, CRENESSITY is distributed by one specialty pharmacy provider.
SPECIALTY-PHARMACY-PROVIDERS	SPECIALTY-PHARMACY-PROVIDERS	92%	We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors.
ETON	Eton Pharmaceuticals, Inc.	72%	Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON g…
ETON	Eton Pharmaceuticals, Inc.	72%	cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for th…
LXEO	Lexeo Therapeutics, Inc.	72%	Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso…
MPLT	MapLight Therapeutics, Inc.	72%	Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT g…
ORANY	ORANY	72%	ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NBIX graph: ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in dis…
SLNO	Soleno Therapeutics, Inc.	72%	Reciprocal relationship from SLNO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from SLNO graph: Reciprocal relationship from NBIX graph: oyager’s receipt of top-line data f…
SLNO	Soleno Therapeutics, Inc.	72%	oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from NBIX graph: oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exe…
SNYNF	Sanofi	72%	oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V…
SPRB	Spruce Biosciences, Inc.	72%	Reciprocal relationship from SPRB graph: her jurisdictions, all of which could seriously harm our business. 85 Table of Contents Item 1B. Unresolv ed Staff Comments. None. For example, cybersecurity …
STQN	Strategic Acquisitions, Inc.	72%	Reciprocal relationship from STQN graph: Reciprocal relationship from NBIX graph: INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates enco…
STQN	Strategic Acquisitions, Inc.	72%	INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TKPH…
TKPHF	Takeda Pharmaceutical Company Limited	72%	ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202…
VTYX	Ventyx Biosciences Inc	72%	Reciprocal relationship from VTYX graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: ket disruptions, whether as a result of the military conflict between Russia…
VYGR	Voyager Therapeutics, Inc.	72%	Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affe…
VYGR	Voyager Therapeutics, Inc.	72%	INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a…
XENE	Xenon Pharmaceuticals Inc.	72%	ons, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 202…
XENE	Xenon Pharmaceuticals Inc.	72%	Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE g…
MITSUBISHI-TANABE-PHARMA-CORPORATION	MITSUBISHI-TANABE-PHARMA-CORPORATION	62%	cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia in May 2017 and for th…
NXERA-PHARMA-UK-LIMITED	NXERA-PHARMA-UK-LIMITED	62%	INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a…
OPERATIONS-NEUROCRINE-BIOSCIENCES-INC	OPERATIONS-NEUROCRINE-BIOSCIENCES-INC	62%	68 NEUROCRINE BIOSCIENCES, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. Business Overview and Summary of Significant Accounting Policies Nature of Operations Neurocrine Biosciences, Inc. an…
SOSEI-HEPTARES-TAKEDA-PHARMACEUTICAL-COMPANY-LIM	SOSEI-HEPTARES-TAKEDA-PHARMACEUTICAL-COMPANY-LIM	62%	INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our a…
TANABE-PHARMA-CORPORATION	TANABE-PHARMA-CORPORATION	62%	oyager’s receipt of top-line data from a first clinical trial for Parkinson’s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) V…
TEVA	Teva Pharmaceutical Industries Limited	62%	Reciprocal relationship from TEVA graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from TEVA g…
TEVA-PHARMACEUTICALS-INDUSTRIES	TEVA-PHARMACEUTICALS-INDUSTRIES	62%	ric patients four years of age and older with classic CAH. We have also established our commercial team and hired our U.S. sales force for CRENESSITY. The successful commercial launch of CRENESSITY d…

Neurocrine Biosciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NBIX-DEBT-11177	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.
NBIX-DEBT	Debt stack $463.5M	90%	Market cache reports total debt of $463.5M.

Neurocrine Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Neurocrine Biosciences, Inc..

Neurocrine Biosciences, Inc. Ownership

Holder	Name	Confidence	Evidence
NBIX-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 698 tracked holders.

Neurocrine Biosciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ALC	Alcon Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
ETON	Eton Pharmaceuticals, Inc.	100.00	1	['customer', 'supplier']

Neurocrine Biosciences, Inc. Supply Chain